Percutaneous Transluminal Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

• DOI: 10.1161/circinterventions.112.971390
• Publication Date: 2012-11-07T09:09:05Z
• Authors: Masaharu Kataoka; Takumi Inami; Kentaro Hayashida; Nobuhiko Shimura; Haruhisa Ishiguro; Takayuki Abe; Yuichi Tamura; Motomi Ando; Keiichi Fukuda; Hideaki Yoshino; Toru Satoh
• Keywords: Male; Hypertension, Pulmonary; Pulmonary Edema; Recovery of Function; Middle Aged; Pulmonary Artery; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Japan; Risk Factors; Reperfusion Injury; Chronic Disease; Natriuretic Peptide, Brain; Humans; Arterial Pressure; Familial Primary Pulmonary Hypertension; Female; Hospital Mortality; Pulmonary Embolism; Angioplasty, Balloon; Biomarkers; Aged

Background— Chronic thromboembolic pulmonary hypertension leads to and right-sided heart failure. The purpose of this study was investigate the efficacy percutaneous transluminal angioplasty (PTPA) for treatment chronic hypertension. Methods Results— Twenty-nine patients with underwent PTPA. One patient had a wiring perforation as complication PTPA died 2 days after procedure. In remaining 28 patients, did not produce immediate hemodynamic improvement at time However, follow-up (6.0 ± 6.9 months), New York Heart Association functional classifications levels plasma B-type natriuretic peptide significantly improved (both P <0.01). Hemodynamic parameters also (mean arterial pressure, 45.3 9.8 versus 31.8 10.0 mm Hg; cardiac output, 3.6 1.2 4.6 1.7 L/min, baseline follow-up, respectively; both Twenty-seven 51 procedures in total (53%), 19 first (68%), reperfusion edema chief complication. Patients severe clinical signs and/or hemodynamics high risk edema. Conclusions— subjective symptoms objective variables, including hemodynamics. may be promising therapeutic strategy Clinical Trial Registration— URL: http://www.umin.ac.jp . Unique identifier: UMIN000001572.